Cutaneous Applications of the Antiviral Drug Cidofovir: A Review

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 May 11

PMID 38730991

Authors

McKayla Poppens

Amanda Ruci

Jeremy Davis

Affiliations

Soon will be listed here.

Abstract

Cidofovir, an antiviral drug approved for cytomegalovirus retinitis, has emerged as an alternative treatment option for virally induced cutaneous and mucocutaneous conditions, as well as being trialed as a treatment for select neoplasms. In this review, we highlight the existing evidence, clinical uses, and rationale of using cidofovir for the treatment of cutaneous pathologies. A PubMed database literature search was conducted to identify relevant articles for inclusion in this review. Cidofovir has several cutaneous applications in various formulations including intravenous, topical, and subcutaneous administrations. Primarily through case reports, case series, and retrospective reviews, cidofovir has demonstrated efficacy in treating a variety of virally induced conditions-verruca vulgaris, herpes simplex virus, molluscum contagiosum-as well as in adjuvant treatment for select neoplasms. The drug has shown efficacy in immunocompromised and immunocompetent adults and children alike. The body of literature supports the use of cidofovir as an effective and well-tolerated treatment for many viral cutaneous pathologies, and encourages further study for its use as an adjuvant therapy for neoplastic disease.

References

Ho H, Woods K, Bronson J, De Boeck H, Martin J, Hitchcock M . Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol. 1992; 41(1):197-202. View

Hicks L, Duvic M . Wiskott-Aldrich syndrome and molluscum contagiosum: a therapeutic challenge after reaction to cidofovir. Int J Dermatol. 2009; 47(12):1304-5. DOI: 10.1111/j.1365-4632.2008.03772.x. View

Gupta M, Bayliss S, Berk D . Topical cidofovir for refractory verrucae in children. Pediatr Dermatol. 2012; 30(1):131-4. DOI: 10.1111/j.1525-1470.2012.01798.x. View

Cundy K, Li Z, Hitchcock M, Lee W . Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab Dispos. 1996; 24(7):738-44. View

Nieto Rodriguez D, Sendagorta Cudos E, Rueda Carnero J, Herranz Pinto P . Atypical Presentation of Herpes Simplex Virus Type 2 Infection Refractory to Treatment With Aciclovir in 2 Hematologic Patients. Actas Dermosifiliogr (Engl Ed). 2017; 110(5):393-397. DOI: 10.1016/j.ad.2017.09.009. View

Calista D, Riccioni L, Coccia L . Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir. Br J Ophthalmol. 2002; 86(8):932-3. PMC: 1771246. DOI: 10.1136/bjo.86.8.932. View

Cleary A, Watson R, McMahon C . Successful treatment of refractory cutaneous warts using topical 3% cidofovir in a child after heart transplant. J Heart Lung Transplant. 2014; 33(9):971-2. DOI: 10.1016/j.healun.2014.02.012. View

Calista D . Topical 1% cidofovir for the treatment of basal cell carcinoma. Eur J Dermatol. 2002; 12(6):562-4. View

Zabawski Jr E, Cockerell C . Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol. 2000; 16(5):414-5. View

10.

Hivnor C, Shepard J, Shapiro M, Vittorio C . Intravenous cidofovir for recalcitrant verruca vulgaris in the setting of HIV. Arch Dermatol. 2004; 140(1):13-4. DOI: 10.1001/archderm.140.1.13. View

11.

Henrickson S, Treat J . Topical Cidofovir for Recalcitrant Verrucae in Individuals with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation. Pediatr Dermatol. 2016; 34(1):e24-e25. PMC: 5488717. DOI: 10.1111/pde.12992. View

12.

Meadows K, Tyring S, Pavia A, Rallis T . Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 1997; 133(8):987-90. View

13.

Anshelevich E, Barbieri J, Kovarik C . Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: A retrospective analysis of 58 patients. J Am Acad Dermatol. 2020; 84(1):206-207. DOI: 10.1016/j.jaad.2020.04.118. View

14.

Alsaleemi A, OConnor C, Irvine A, Leahy T . Topical cidofovir for the treatment of recalcitrant viral warts and molluscum contagiosum in Jacobsen syndrome. Pediatr Dermatol. 2020; 37(6):1191-1192. DOI: 10.1111/pde.14355. View

15.

Grone D, Treudler R, de Villiers E, Husak R, Orfanos C, Zouboulis C . Intravenous cidofovir treatment for recalcitrant warts in the setting of a patient with myelodysplastic syndrome. J Eur Acad Dermatol Venereol. 2006; 20(2):202-5. DOI: 10.1111/j.1468-3083.2006.01380.x. View

16.

Lau W, Lau C, Frangos J, Nambudiri V . Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities. Ther Adv Infect Dis. 2023; 10:20499361231165862. PMC: 10088403. DOI: 10.1177/20499361231165862. View

17.

Marini A, Niehues T, Stege H, Ruzicka T, Hengge U . Plantar warts in twins after successful bone marrow transplantation for severe combined immunodeficiency. J Dtsch Dermatol Ges. 2006; 4(5):417-20. DOI: 10.1111/j.1610-0387.2006.05944.x. View

18.

Coates M, Patel J, Powers C, Burton C . Laser-Assisted Delivery of Topical Cidofovir in the Treatment of Plantar Warts. J Drugs Dermatol. 2019; 18(7):663-665. View

19.

De Clercq E . Cidofovir for the Treatment of Molluscum Contagiosum Virus. Viruses. 2022; 14(11). PMC: 9696735. DOI: 10.3390/v14112484. View

20.

Oh B . Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection. Ann Dermatol. 2021; 32(4):273-279. PMC: 7992651. DOI: 10.5021/ad.2020.32.4.273. View